Leukemia

The FDA granted priority review to quizartinib for treatment of certain patients with acute myeloid leukemia.

Conception via assisted reproductive technology appeared associated with increased risk for childhood cancers compared with natural conception or subfertility and nonassisted reproductive technology conception methods, study results showed.

The FDA granted orphan drug designation to KITE-222, an investigational chimeric antigen receptor T-cell therapy, for treatment of adults with relapsed or refractory acute myeloid leukemia.

Gerontology researchers and hematologic oncology investigators from Brigham and Women’s Hospital and Dana-Farber Cancer Institute have devised a scale for assessing high-risk medications in older patients with blood cancers.

September is Childhood Cancer Awareness Month.

Rates for CV admissions among patients with cancer has increased, according to a study published in the European Heart Journal Quality of Care & Clinical Outcomes.Primary CV admissions are highest among patients with hematological cancer with the most common cause of admission being heart failure, according to the study.

A third dose of the mRNA-1273 vaccine for COVID-19 significantly improved SARS-CoV-2 antibody concentrations among patients with hematologic malignancies who previously received two doses, results of a prospective study showed.

Younger patients who received higher doses of tisagenlecleucel for advanced B-cell acute lymphoblastic leukemia achieved better outcomes, according to results of a retrospective study.

Perhaps no one has been better prepared to become a leader in the field of cancer cellular immunotherapy than Marcela V. Maus, MD, PhD.

The FDA granted fast track and rare pediatric disease designations to WU-CART-007 for treatment of relapsed or refractory T-cell acute lymphoblastic leukemia, according to a press release from the agent’s manufacturer.